<DOC>
	<DOC>NCT02709655</DOC>
	<brief_summary>Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric patients (age 7 to 11 years)</brief_summary>
	<brief_title>Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>1. The patient has Major depressive disorder (MDD), diagnosed according to DSM5™. 2. The patient has a CDRSR total score ≥45 at the Screening Visit and the Baseline. 3. The patient has a Clinical Global Impression Severity of Illness (CGIS) score ≥4 at the Screening Visit and the Baseline. 4. The patient is a boy or girl, aged ≥7 and &lt;12 years at Screening Visit 5. The patient has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form. 1. The patient has participated in a clinical study &lt;30 days prior to the Screening Visit. 2. The patient has previously participated in a study with vortioxetine. Other protocol defined inclusion and exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>paediatric</keyword>
</DOC>